

VX21-522-001: A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

1. 18 to 65 years old 2. Stable cystic fibrosis disease 3. FEV1 at least 40% 4. Specific CFTR gene mutations

Exclusion Criteria:

1. Uncontrolled asthma in the last year 2. Oxygen saturation without oxygen therapy is >94% 3. Severe liver disease

Conditions & Interventions

Interventions:

Drug: IVA, Drug: VX-522 mRNA therapy

Conditions:

Rare Diseases, Breathing, Lung & Sleep Health

Keywords:

Cystic Fibrosis, CF

More Information

Description: This is a clinical research study exploring the safety and tolerability of a single dose of VX-522 for people with cystic fibrosis (CF) who are not expected to benefit from CFTR modulators.

Study Contact: Mary Bailey - mpbailey@umn.edu

Principal Investigator: Joanne Billings

IRB

Number: SITE00001585

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.